TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SUFLAVE

MAGNESIUM SULFATE
Approved 2023-06-15
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2023-06-15
Routes
ORAL
Dosage Forms
FOR SOLUTION

SUFLAVE Approval History

Loading approval history...

What SUFLAVE Treats

1 FDA approvals

Originally approved for its first indication in 2023 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SUFLAVE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

SUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUFLAVE is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

SUFLAVE Patents & Exclusivity

Latest Patent: Aug 2044
Exclusivity: Jun 2026

Patents (3 active)

US12290529 Expires Aug 2, 2044
US12433914 Expires Jun 14, 2044
US12239659 Expires Jun 14, 2044

Exclusivity

NP Until Jun 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.